Affimed

Affimed Equity

Delisted

The The Equity of Affimed (AFMD) as of Nov 19, 2026 is 57.81 M EUR. In the previous year, The Equity was 152.92 M EUR — a change of -62.20% (lower).

Equity

57.81 MEUR

YoY

-62.20%

Last updated:

In 2023, Affimed's equity was 57.81 M EUR, a -62.20% increase from the 152.92 M EUR equity in the previous year.

The Affimed Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
38.75 M EUR
Jan 1, 2017
31.58 M EUR
Jan 1, 2018
40.13 M EUR
Jan 1, 2019
38.67 M EUR
Jan 1, 2020
71.99 M EUR
Jan 1, 2021
135.95 M EUR
Jan 1, 2022
152.92 M EUR
Jan 1, 2023
57.81 M EUR
The Affimed Equity history
YEAREquityYoY
57.81 MEUR-62.20%
152.92 MEUR+12.48%
135.95 MEUR+88.84%
71.99 MEUR+86.19%
38.67 MEUR-3.64%
40.13 MEUR+27.07%
31.58 MEUR-18.51%
38.75 MEUR-42.40%
67.27 MEUR+111.59%
31.80 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Affimed's Equity

Affimed's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Affimed's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Affimed's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Affimed's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Affimed’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Affimed stock

The Equity of Affimed is 57.81 M EUR in 2023.

The Equity of Affimed changed from 152.92 M EUR to 57.81 M EUR, representing a -62.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Affimed since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Affimed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Affimed

All Key Metrics — Affimed